SPRB

Spruce Biosciences, Inc.

A clinical-stage biopharmaceutical company developing drug therapies for rare endocrine (hormone) disorders. Its lead experimental medicine, tildacerfont, is being studied for people living with congenital adrenal hyperplasia, a rare genetic condition that disrupts the body's hormone production. Founded in 2013 and based in South San Francisco, the company went public on the US stock market in 2021.